ASTERDM Aster DM Healthcare Q3 FY26 results (Oct–Dec 2025) and concall
Aster DM Healthcare reported a strong Q3 FY26, with combined proforma revenue growing 15% YoY to INR 2,366 crore and operating EBITDA up 22% YoY to INR 503 crore. Aster's standalone revenue increased 13% YoY to INR 1,186 crore, while QCIL's revenue grew 17.3% YoY to INR 1,181 crore, demonstrating robust growth across both entities. The quarter saw a one-time exceptional expense of INR 27.9 crore impacting PAT and some softness in the K&M cluster, but overall performance was driven by strong growth in Kerala, a turnaround in Aster Labs, and strategic capacity expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 13.0%, net profit down 7.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 +10% | 1,186 +13% |
| EBITDA | 217 | 186 | 182 | 202 | 236 +9% | 202 +9% |
| Net profit | 106 | 64 | 86 | 94 | 121 +14% | 59 −8% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
